By using well-known and trusted ELISA technology to assess three key biomarkers—bacterial proliferation, intestinal inflammation, and gliadin sensitivity—the Canine CE-IBD Assay can deliver one of two results: Consistent with CE/IBD or Not Consistent with CE/IBD.
From there, you can tailor your diagnostic and treatment plan based on the biomarkers.
Anti-OmpC Porins Surface Antigens IgA antibodies: Single best marker to differentiate IBD in canine patients
Anti-Canine Calprotectin IgA antibodies
Anti-Gliadin IgA antibodies
This tool can be helpful at any point in the diagnostic workup, from serving as an early indicator to evaluating a pet's progress. A thorough workup of the gastrointestinal (GI) signs is still recommended, including ruling out parasites, investigating the presence of a GI foreign body, identifying neoplasia with diagnostic imaging, and additional testing that could include endoscopy and biopsies.
Available exclusively through Antech, RenalTech™ is a breakthrough in predictive medicine. Powered by artificial intelligence, RenalTech™ uses common serum and urine diagnostics to predict whether a cat will develop chronic kidney disease in the next two years—with greater than 95% accuracy.
Rapid access to effective treatment for CE/IBD is the goal. It’s also essential as the disease can have a serious impact on a dog’s health and overall well-being. An affected dog generally experiences vomiting and/or diarrhea, poor appetite, weight loss, flatulence and abdominal discomfort for approximately at least 3 weeks before CE/IBD can be ruled in with certainty, though many practitioners may begin to suspect the condition earlier based on clinical experience.